Hematology trials are hard to fill. Eligibility often depends on lab values, cytogenetics, prior lines of therapy and transplant history, and many patients are treated far from the sites running the study.
The consequences are well documented: around 20% of cancer clinical trials fail because they cannot enroll enough patients (JCO Oncology Practice, 2021). In hematology, the right recruitment partner can be the difference between a study that closes early and one that reaches its target.
This list covers CROs, specialist site networks and patient navigation services with real hematology experience.
Top 10 Best Hematology Clinical Trial Recruitment Companies in 2026
1. Patiro
Patiro is a Danish patient recruitment and site support company with experience in B-cell malignancies, follicular lymphoma, polycythemia vera, myelofibrosis and myelodysplastic syndromes. In hematology, eligibility often depends on lab values, prior lines of therapy and transplant history, so Patiro's medical team pre-screens every candidate 1-on-1, in the local language, before referral. Patients with blood cancers are often treated far from research sites, and Patiro plans travel and logistics support with sites where the protocol allows. It recruits in 44+ countries, offers a pay-per-enrolled-patient model and also supports rescue studies that have fallen behind.
2. IQVIA
IQVIA runs a hematology-oncology center of excellence and reports 310 malignant hematology trials in the past five years, with more than 45,000 patients enrolled across 32 countries. It also covers classical hematology, such as sickle cell disease and bone marrow failure syndromes. Its data-driven site selection aims to find eligible patients beyond a site's known population. For large global hematology programs, its scale is hard to match.
3. Parexel
Parexel's hematology team covers lymphoma, AML, MDS, multiple myeloma and benign disorders such as hemophilia and sickle cell disease. In MDS it reports 78 alliance members and more than 400 experienced principal investigators worldwide, and it has deployed dedicated clinical trial liaisons to recover studies that fell behind on screening. Strong for sponsors who want specialist investigator relationships.
4. Medpace
Medpace runs hematology-oncology trials across leukemia, lymphoma and myeloma as well as non-malignant hematology, including pediatric hematology/oncology and stem cell transplantation. Integrated central labs help with the complex sampling many hematology protocols require. A good fit for full-service programs that want one partner for operations and labs.
5. Fortrea
Fortrea designs, runs and manages hematology trials from early phase through registrational and post-approval studies, and draws on decades of work with large pharma, biotech and research organizations.
6. PPD (Thermo Fisher Scientific)
PPD reports experience in more than 700 oncology and hematology trials, covering immuno-oncology, targeted therapy and cell and gene therapy, including CAR-T. Its early-phase group combines its own facilities with a site network for phase I and IB work. Relevant for sponsors running cell therapy programs in blood cancers.
7. START Center for Cancer Research
START is an early-phase site network that focuses on first-in-human and phase I cancer trials, including malignant hematology studies in leukemia, lymphoma and multiple myeloma. It offers one contract and one budget across its locations, which shortens activation for early hematology programs.
8. TD2
TD2 is an oncology-focused CRO with hematologic malignancy experience in AML, MDS, myelofibrosis, lymphoma and multiple myeloma. It builds recruitment and retention strategies specifically for hard-to-enroll hematology indications. A specialist option for small and mid-sized biotechs.
9. Blood Cancer United Clinical Trial Support Center
The Leukemia & Lymphoma Society, now Blood Cancer United, runs a free Clinical Trial Support Center where oncology nurse navigators help patients with blood cancers find and enroll in trials. The service has shown that it takes many conversations to get one patient enrolled; LLS has reported 25 navigator interactions per enrollment (Healio, 2021). It is not a vendor, but it is where many US patients go for help.
10. ResearchMatch
ResearchMatch is a free, not-for-profit registry that connects volunteers with researchers in the United States, used by the NIH Clinical Center. It is not hematology-specific, so treat it as a supplement for US academic studies rather than a core channel.
Why Hematology Clinical Trial Recruitment Can Be Challenging
Hematologic diseases are often split into small, molecularly defined subgroups. A trial may want a specific mutation, a particular number of prior therapies or patients who are not eligible for transplant, which leaves only a fraction of the diagnosed population.
Timing is the second problem. Patients with aggressive disease may need treatment before a trial can screen them, while patients with chronic conditions such as myeloproliferative neoplasms may be stable on current therapy and see little reason to switch.
Geography adds to both. Specialist hematology care is concentrated in large centers, so many eligible patients live hours away from a site and need travel support to take part.
How to Choose the Right Hematology Clinical Trial Recruitment Partner
Check Their Indication Experience
Ask which hematologic indications the partner has recruited for. General oncology experience is not enough. MDS, myelofibrosis and lymphoma each have their own care pathways and patient communities.
Ask Who Does the Pre-Screening
Hematology criteria are technical. Pre-screening should be done by medically trained staff who can ask about lab results, prior regimens and transplant status, and who know what records to request.
Plan for Travel and Burden
Find out how the partner handles patients who live far from sites. Travel support, flexible scheduling and clear expectations before referral protect both enrollment and retention.
Combine Vendors and Navigators
Commercial partners and nonprofit navigation services reach different patients. Many successful programs use both.








